n-Hexane, chloroform and ethyl acetate fractions obtained from methanol extracts of the wood and roots of Esenbeckia almawillia (Rutaceae) were tested against five tumor cells lines (HL-60, CEM, B-16, HCT-8 and MCF-7). The most active fractions were the less polar ones (IC 50 from 1.7 to 5.3 μg/mL) and these were subjected to column chromatography, allowing the isolation of the alkaloid 3,3-diisopentenyl-N-methyl-2, 4-quinoldione (1) in high yields. Alkaloid 1 was bioassayed and gave an IC 50 value in the range 9.2 to >25 μg/mL. Derivatives 2-12, obtained by chemical modifications of 1, were tested and lower IC 50 values were found for compounds 4 (IC 50 from 2.8 to 17.0 μg/mL), 10 (IC 50 from 5.9 to 15.8 μg/mL) and 11 (IC 50 from 6.7 to 14.8 μg/mL).
Discovery of biologically active compounds is one of the main objectives of natural products chemistry. Among the several classes of secondary metabolites from plants, quinolone alkaloids deserve special attention for being associated with, for example, antitumor [1] , fungicidal [2] , anti-HIV [3] , antimycobacterial [4] , and antibiotic [5] activities. Phytochemical investigation of the wood [6] and essential oils [7] from Esenbeckia almawillia (Rutaceae) allowed the isolation of 3,3-diisopentenyl-N-methyl-2,4-quinoldione (1) . In the search for biologically active compounds from Brazilian plants, we report herein the antitumor and antimycobacterial activities of extracts from roots and wood of E. almawillia, as well as of alkaloid 1 and derivatives 2-12, obtained by chemical modification. Compounds 3 and 5-9 are being reported for the first time in the literature.
n-Hexane, chloroform and ethyl acetate fractions obtained after partition of the methanol extracts from wood (EAWM-H, EAWM-C and EAWM-EA) and roots (EARM-H, EARM-C and EARM-EA) were tested against tumor cell lines (Table 1) . Antitumor activities decreased with increasing fraction polarity. The highest activities were found in the n-hexane fractions from both wood (EAWM-H) and roots (EARM-H), which were chromatographed leading to the isolation of the alkaloid 3,3-diisopentenyl-Nmethyl-2,4-quinoldione (1) in high yields (40.0% from EAWM-H [6] and 9.6% from EARM-H). This compound was bioassayed and considerable higher IC 50 values (9.2 to >25) were observed for all tested cell lines, suggesting that this compound was not the only one responsible for the observed antitumor activity of fractions EAWM-H and EARM-H. In order to improve the antitumor activity of alkaloid 1, structure-activity relationship was studied through derivatives 2-12 ( Figure 1 ) obtained by chemical modifications of 1. The following modifications were performed: a) reduction of the ketone carbonyl leading to derivative 2, followed by O-alkylation (3 and 5-9), O-acylation (4) and hydrogenation of the isoprenyl group (10); b) hydrogenation of the isoprenyl groups of 1 providing derivative 11; c) intramolecular cyclization of 1 leading to 12. and containing an ester carbonyl moiety, clearly improved the antitumor activity. In this last case, we can suggest that the greater activity of 4, when compared to 1, is associated with either steric (the sp 3 oxygen atom as spacing group) or electronic (ester instead of ketone carbonyl) factors. The influence of the isoprenyl group for the molecule activity was investigated using derivatives 10 and 11. Both compounds displayed greater activity when compared to 1, suggesting that the change of the alkenyl to alkyl group in this moiety is an important feature for the molecule activity. Moreover, this change seems to be more important for the activity than the presence of the carbonyl group. The more dramatic change in the structure of 1 to provide derivative 12 did not improve the antitumor activity.
In summary, derivatives 4, 10 and 11 were more active than alkaloid 1, suggesting the influence of the carbonyl and isoprenyl groups on antitumor activity. 
3,3-Diisopentenyl-4-methoxy-N-methyl-2-quinolone (3)
Compound 2 (20.0 mg, 0.064 mmol) was methylated with MeI (20.0 mg, 0.14 mmol), KOH (15.0 mg, 0.27 mmol) and DMSO (3.0 mL), according to a literature procedure [8] . 
3,3-Diisopentenyl-4-butyl-N-methyl-2-quinolone (7)
Compound 2 (25.0 mg, 0.08 mmol) was dissolved in dry benzene (3.0 mL) and allowed to react with butyl bromide (0.20 mmol) and KOH (0.35 mmol), according to the literature procedure [9] . Purification by column chromatography on silica gel by elution with n-hexane: ethyl acetate (9:1) afforded compound 7 as a yellowish oil (14.5 mg) in 50.0% yield. 
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3,3-Diisopentenyl-4-hexyl-N-methyl-2-quinolone (8)
Compound 2 (25.0 mg, 0.08 mmol) was dissolved in dry benzene (3.0 mL) and allowed to react with hexyl bromide (0.25 mmol) and KOH (0.37 mmol) following the literature procedure [9] . Purification by column chromatography on silica gel by elution with n-hexane: ethyl acetate (9.5:0.5) yielded compound 8 as a yellowish oil (12.0 mg, 37.5%). Antitumor activity: Fractions and compounds 1-12 (except 5) were evaluated for their cytotoxicity using MCF-7 (human breast), HCT-8 (human colon), B16 (murine melanoma), HL60 and CEM (human leukemias) cell lines (National Cancer Institute, Bethesda, MD, USA) using the MTT assay [12] . This assay is based on the reduction of the yellow colored 3-(4',5'-dimethylthiazol-2'-yl)-2,5-diphenyltetrazolium bromide (MTT) by mitochondrial dehydrogenase of metabolically active cells to a purple-blue formazan. The compounds (0.39-25.0 μg/mL) were incubated for 72 hours in cell culture media, before the MTT assay. The IC 50 values and their confidence intervals were obtained by nonlinear regression using Graph Pad Prism Software.
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Antimycobacterial activity:
The antimycobacterial activity of compounds 1, 3, 5, 8 and 9 was evaluated against Mycobacterium tuberculosis H37Rv (ATCC 27294) using the microplate Alamar Blue assay [12] . Isolated compounds were dissolved in dimethylsulfoxide (DMSO) at 500 μMol and serially diluted in Middlebrook 7H9 broth medium before inoculation. Concentrations tested were from 0.06 to 125 μMol. Rifampicin was used as control and bioassays were performed at least in three independent experiments. The visual minimal inhibitory concentration (MIC) was defined as the lowest drug concentration that prevented mycobacterial growth.
